Skip to content
University of Colorado Anschutz Medical Campus CU Anschutz
  • Webmail
  • UCD Access
  • Canvas
  • Quick Links
 

Tools & Resources

  • Events Calendar
  • Newsroom
  • Strauss Health Sciences Library
  • Department A-Z Directory
  • Campus Directory
  • Leadership
  • Faculty & Staff Resources
  • Supporter & Alumni Resources
  • Student Resources
  • Campus Map
  • University Policies
  • Give Now

CU Campuses

  • CU Anschutz Medical Campus
  • CU Boulder
  • CU Colorado Springs
  • CU Denver
  • CU System
  • CU Online

CU Anschutz Medical Campus

  • School of Dental Medicine
  • Graduate School
  • School of Medicine
  • College of Nursing
  • Skaggs School of Pharmacy and Pharmaceutical Sciences
  • Colorado School of Public Health

Division of Medical Oncology

School of Medicine

  • Home
  • Leadership
    • Division Head | Wells Messersmith, MD, FACP
    • Deputy Division Head | Virginia Borges, MD, MMSc
  • Research
  • Cancer Care
    • CARE Clinic
    • Clinical Trials
    • Find a Provider
    • Satellite Locations
  • Education
  • Giving
  • Newsroom
  • Division Resources
  • Division Directory
    • Clinical & Research Faculty
    • Research Services Personnel
    • Administrative Staff
University Quick Links
  • Home
  • Research
  • Lung Cancer
  • Schenk Research Lab

SCHENK RESEARCH LAB

Research Focus

The Schenk Lab studies the lung cancer tumor microenvironment, a diverse collection of cell types that can be found in and around lung tumors.  Dr. Schenk is focused on the immune cells within the tumor and how specific sub-types can contribute to treatment resistance and ultimately hopes to use lab findings to improve therapy for patients with lung cancer.  

Erin Schenk, MD, PhD

Principal Investigator

Stevie Phelabaum, BS

Research Services Professional

Greg Reis, BS

Research Services Senior Professional

Selected Publications

Pacheco JM, Camidge DR, Doebele RC, Schenk E. A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer.” Front Oncol. 2019;9:195. PMID 30984621

Kleczko EK, Kwak JW, Schenk EL, Nemenoff RA. “Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer.” Front Immunol. 2019;10:954.  PMID 31134065

Bullock B, Kimball A, Poczobutt J, Li H, Kwak J, Neuwelt A, Johnson A, Kleczko E, Kaspar R, Wagner E, Hopp K, Schenk E, Weiser-Evans M, Clambey E, and Nemenoff R.  “Tumor-Intrinsic Response to IFNg Shapes the Tumor Microenvironment and Anti-PD-1 Response in NSCLC" In press, Life Sci Alliance 2019 Jun;2(3).  PMID 31133614

Schenk EL, Mandrekar SJ, Dy GK, Aubry MC, Tan AD, Dakhil SR, Sachs BA, Nieva JJ, Bertino E, Lee Hann C, Schild SE, Wadsworth TW, Adjei AA, and Molina JR.  “A randomized double-blind phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG (Alliance) N0923 Study.”  Journal of Thoracic Oncology, October 2019.  PMID 31605793

Medical Oncology (SOM)

CU Anschutz

Research I South

12801 East 17th Avenue

8122

Aurora, CO 80045


720-848-0300

Facebook Twitter
School
  • School of Medicine Home
  • Find a Doctor
  • Find a Researcher
  • Departments
  • Contact Us
  • Donate
  • School Profiles
General
  • Affiliate/Partner Hospitals
  • CU Medicine
  • A-Z Index
  • Directory
  • Map and Parking
  • Webmail
Students
  • Apply Now
  • Alumni
  • Canvas
  • Health Science Library
  • Student Life
  • Colorado Springs Branch
  • Contact Us
  • Website Feedback
  • CU System
  • Privacy Policy
  • Terms of Use
  • Accessibility
  • Accreditation
  • Employment
  • Give Now
 

© 2023 The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.

CMS Login

Webmail

UCD Access

Canvas

Opens in a new window Opens document in a new window